Banner
  • Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

FDA vs. MDMA; home health aide health; illegal opioid sales – Morning Medical Update

News
Article

The top news stories in medicine today.

Doctor morning desk: © Alena Kryazheva – stock.adobe.com

© Alena Kryazheva – stock.adobe.com

Aid for the aides

As America becomes a grayer nation, many older adults want to stay in their own homes instead of going to a nursing home. As a result, home health aides “are a rapidly growing workforce trained and certified to provide personal and medical care, as well as emotional support, in the home,” said a new study, “Mental Health and Well-Being Among Home Health Aides.” “For our patients to do well, we need to support this workforce,” said a physician who has studied the work of home health aides.

Voting no on MDMA

A Food and Drug Administration (FDA) advisory committee this month voted against allowing the drug MDMA, also known as ecstasy, for treatment of post-traumatic stress disorder. It was the FDA’s first vote on considering a Schedule I psychedelic drug for therapeutic use and is considered a major setback for advocates of psychedelics to treat mental health disorders. Read a report on the vote and watch a video of an expert’s reaction in Psychiatric Times, a sister publication of Medical Economics.

Alleged opioid sales

In New York, a physician and a pharmacist could face up to 20 years in prison for illegally selling oxycodone, according to federal investigators. The two were arrested this month and a U.S. Department of Justice news release about the case included a copy of a hand-written menu with per-pill prices for backdoor sales. “They allegedly used their positions as health care professionals as a cover for what amounted to no more than common drug dealing operations,” said the U.S. attorney prosecuting the case.

Related Videos